Supplementary Figure 4: Optogenetic stimulation of additional BNST and hypothalamus subpopulations.
(a) Representative image of AAV-DIO-eYFP expression in adlBNST and admBNST of Vgat-Cre mouse. (b) Vgat-BNST-ChR2 optogenetic stimulation is rewarding in the RTPT (n=4 eYFP, n=5 ChR2-eYFP, two-way RM-ANOVA; ChR2 x stimulation interaction: F2,14 = 4.16, p = 0.038, Bonferroni post-hoc comparisons *p < 0.05, ***p < 0.0001 vs. Vgat-BNST-eYFP control group). Centre and error bars are mean ± S.E.M. (c) Representative image of AAV-DIO-eYFP expression in ovBNST of Drd1-Cre mouse. (d) Drd1-BNST-ChR2 optogenetic stimulation is aversive in the RTPT (n=4–8 mice per group, two-way RM-ANOVA; ChR2 x stimulation interaction: F2,20 = 12.38, p = 0.0003, Bonferroni post-hoc comparisons ***p < 0.005 vs. Drd1-BNST-eYFP control group). Centre and error bars are mean ± S.E.M. (e) Representative image of AAV-DIO-ChR2-eYFP expression in admBNST of Six3-Cre mouse. (f) Six3-BNST-ChR2 optogenetic stimulation is rewarding in the RTPT (n=4 per group, two-way RM-ANOVA; ChR2 x stimulation interaction: F2,12 = 8.79, p = 0.0045, Bonferroni post-hoc comparisons ***p < 0.001 vs. Six3-BNST-eYFP control group). Centre and error bars are mean ± S.E.M. (g) Representative image of AAV-DIO-eYFP expression in PVN of Crf-Cre mice. (h) Crf-PVN-ChR2 optogenetic stimulation is aversive in the RTPT (n=4 eYFP, n=6 ChR2-eYFP mice, two-way RM-ANOVA; ChR2 x stimulation interaction: F2,16 = 2.33, p = 0.13, Bonferroni post-hoc comparisons *p < 0.05 vs. Crf-PVN-eYFP control group). Centre and error bars are mean ± S.E.M. Scalebars: all 100 μm.
